Compare AU
Compare AAA vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Australian High Interest Cash ETF (AAA) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
AAA | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 162 | 65 |
Median incremental investment | $5,043.50 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,931.16 | $1,955.77 |
Average age group | > 35 | 26 - 35 |
Key Summary
AAA | DRUG | |
|---|---|---|
Strategy | AAA.AX was created on 2012-03-06 by BetaShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. The Fund aims to provide exposure to Australian cash, with attractive and regular incomedistributions that exceed the 30 day Bank Bill Swap Rate (after fees and expenses). | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (100.00 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Communication Services (100.00 %) | Other (76.17 %) Communication Services (33.53 %) Health Care (23.66 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.18 % | 0.57 % |
Key Summary
AAA | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.18 % | 0.57 % |
Price | $50.16 | $7.61 |
Size | $4.304 billion | $169.381 million |
10Y return | 0.06 % | N/A |
Annual distribution yield (5Y) | 2.40 % | 1.89 % |
Market | ASX | ASX |
First listed date | 07/03/2012 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
AAA | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 162 | 65 |
Median incremental investment | $5,043.50 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,931.16 | $1,955.77 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
AAA | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
AAA | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |